Incyte Corporation (INCY) Stock Price & How to Invest

Last updated November 2026

Short answer

Incyte (INCY) is a mid-cap biopharmaceutical company, worth about $23 billion as of October 2026, built around Jakafi (ruxolitinib), a JAK inhibitor for blood cancers, plus the Opzelura skin cream and a growing oncology and dermatology pipeline. Revenue reached about $5.8 billion over the last twelve months, and the investment picture centers on whether newer products and pipeline assets can replace Jakafi revenue before its US exclusivity ends in December 2028.

INCY stock price

As of 2026-11-16, Incyte Corporation (INCY) last closed at $120.27, up 15.5% over the past year. Over the past 52 weeks it has traded between $90.30 and $129.93.

INCY last close
$120.27
1 day
-0.58%
1 month
+6.37%
1 year
+15.46%
52-week range
$90.30 to $129.93
Last close
2026-11-16

Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Incyte Corporation's investor relations page. Walnut is informational, not investment advice.

INCY key stats

At $120.27 on November 16, 2026, Incyte Corporation (INCY) has a market cap of $24.5B and a P/E of 61.4 on trailing earnings (13.9 on forward earnings).

Market cap
$24.5B
P/E (trailing)
61.4
P/E (forward)
13.9
EPS (trailing 12 months)
$1.96
Price to book
4.3
Beta
0.78

Market cap, P/E and yield are measured at the $120.27 price on November 16, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.

What's new with Incyte Corporation (INCY)?

The last two weeks for Incyte Corporation, as of November 17, 2026: the price move, the next earnings date, what the company filed with the SEC, and what analysts changed.

  • INCY closed at $120.27 on November 16, 2026, down 1.3% over the past five trading days (from $121.89).
  • On November 13, 2026, Incyte Corporation filed an 8-K with the SEC reporting other events (Item 8.01). Read the 8-K on sec.gov
  • On November 5, 2026, Leerink Partners lowered its target to $150.00 from $154.00 (Outperform).

Prices are daily closes from Yahoo Finance. Filings are read from SEC EDGAR every six hours. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.

Incyte Corporation (INCY) latest quarter

Incyte reported revenue of $1.6 billion for Q3 2026, up 14% from a year earlier (Incyte, Oct 29, 2026).

Revenue
$1.6 billion
up 14% from a year earlier
Diluted EPS (GAAP)
-$3.86
n/a
Total net sales
$1.3 billion
up 14% from a year earlier

Source: Incyte Q3 2026 results, Oct 29, 2026. Full earnings breakdown

What does Incyte Corporation (INCY) do?

Incyte Corporation is a Wilmington, Delaware based biopharmaceutical company that discovers, develops, and commercializes drugs in oncology, hematology, and dermatology. Its flagship product is Jakafi (ruxolitinib), an oral JAK inhibitor approved for myelofibrosis, polycythemia vera, and graft-versus-host disease, which still generates the largest share of company revenue (roughly $758 million in Q1 2026, up about 7%). Beyond Jakafi, Incyte sells the topical cream Opzelura (ruxolitinib) for atopic dermatitis and vitiligo, plus a widening hematology and oncology lineup including Monjuvi/Minjuvi, Niktimvo, and Zynyz, and it funds a broad clinical pipeline of oncology and immunology candidates. In September 2026 the FDA approved Atebrioz (zilurgisertib), an Incyte-discovered ALK2 inhibitor, for fibrodysplasia ossificans progressiva; Incyte licensed US commercialization to Mirum Pharmaceuticals.

The investment picture is defined by one number and one date: Jakafi's US loss of exclusivity in December 2028. Incyte is profitable and cash-rich (about $4.5 billion in cash against roughly $38 million of debt as of mid-2026) and growing fast. Revenue over the last twelve months was about $5.8 billion with net income near $1.6 billion, and Q2 2026 revenue of about $1.67 billion rose roughly 38% year over year, beating analyst estimates by about 11%, with EPS of $3.09 against a $2.15 consensus. Management's stated goal is to build $3 billion to $4 billion of non-Jakafi revenue by the time the patent cliff hits. As of October 16, 2026 the shares closed near $114, up about 12% year to date and about 30% over the past year, though down about 9% over the past month. Q3 results are due October 29, 2026, and analysts expect a reported loss of roughly $3.84 per share on about $1.48 billion of revenue, which points to a large one-time charge rather than a collapse in sales. The bull case is that Opzelura, newer launches, and pipeline readouts (such as the vitiligo candidate povorcitinib and combination programs) offset the decline; the bear case is heavy dependence on a single aging drug, clinical trial risk, and a setback such as the FDA's rejection of an extended-release Jakafi formulation.

What's driving Incyte Corporation (INCY)?

1. Jakafi franchise still growing near-term

Jakafi remains the profit engine, posting roughly $758 million in Q1 2026 net sales on about 6% prescription demand growth across myelofibrosis, polycythemia vera, and GVHD. That cash flow funds the entire R&D and commercial buildout, and total company revenue jumped to about $1.67 billion in Q2 2026. The near-term question is how long Incyte can keep growing the franchise before generic ruxolitinib arrives.

2. Non-Jakafi revenue diversification

Opzelura grew about 20% to roughly $143 million in Q1 2026, and the hematology/oncology portfolio (Niktimvo, Monjuvi/Minjuvi, Zynyz) more than doubled to around $204 million. Niktimvo picked up regulatory approval in Brazil in October 2026 through partner Knight Therapeutics. Management targets $3 billion to $4 billion of non-Jakafi revenue by the 2028 cliff. The pace of these ramps is the central bull-case variable.

3. Pipeline and combination strategy

Incyte is advancing candidates such as the vitiligo drug povorcitinib and combination programs pairing Jakafi with a BET inhibitor and other assets. The ALK2 inhibitor zilurgisertib reached the market in September 2026 as Atebrioz for fibrodysplasia ossificans progressiva, licensed to Mirum Pharmaceuticals in the US, which gives Incyte its first approval from that program. Positive late-stage readouts could open new indications and extend the ruxolitinib platform. Pipeline outcomes are the swing factor for revenue beyond 2028.

4. Strong balance sheet and profitability

The company held about $4.5 billion in cash against only about $38 million of debt at the end of Q2 2026, and generated roughly $1.2 billion of free cash flow over the last twelve months. CEO Bill Meury has pointed to strategic business development alongside sales growth, and that financial cushion gives Incyte capacity to fund internal R&D or pursue deals to backfill the Jakafi cliff. Capital allocation decisions will shape the diversification outcome.

What are the risks to Incyte Corporation (INCY)?

The dominant risk is revenue concentration: Jakafi still drives the majority of sales and faces US loss of exclusivity in December 2028, after which generic ruxolitinib is expected to erode the franchise. Pipeline and launch execution carry real uncertainty, as shown by the FDA's rejection of the once-daily extended-release Jakafi formulation, and clinical trials can fail at any stage. Reported earnings can also swing sharply: analysts expect a loss of about $3.84 per share for Q3 2026 even with revenue near $1.48 billion, and full-year 2026 EPS consensus of about $3.12 is well below the $7.85 trailing figure. Full-year revenue guidance given with Q2 also came in below analyst expectations. Competition is intensifying from larger peers with deeper resources in both oncology (Bristol Myers Squibb, Novartis, AbbVie) and inflammation/dermatology (AbbVie's Rinvoq, Eli Lilly's Olumiant, Pfizer, Regeneron). Morningstar has downgraded Incyte's economic moat toward none, citing the looming patent loss. If non-Jakafi revenue does not scale to the $3 billion to $4 billion goal in time, the company could face a revenue gap late this decade.

What is the Incyte Corporation (INCY) forecast?

24 analysts publish price targets on INCY, averaging $131.50 as of November 2026, or +9.3% against the $120.27 share price on November 16, 2026. The published targets run from $100.00 to $157.00, a moderate spread, and the ratings split 13 buy, 14 hold, 1 sell. Over the last six months there have been 9 raises and 2 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full INCY forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

Is INCY a buy or a sell?

We give no verdict on Incyte Corporation. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Jakafi franchise still growing near-term. Jakafi remains the profit engine, posting roughly $758 million in Q1 2026 net sales on about 6% prescription demand growth across myelofibrosis, polycythemia vera, and GVHD. The most optimistic published target, $157.00, assumes this works close to its best case.

The case against. The dominant risk is revenue concentration: Jakafi still drives the majority of sales and faces US loss of exclusivity in December 2028, after which generic ruxolitinib is expected to erode the franchise. The most pessimistic target, $100.00, is roughly what INCY is worth if this bites instead.

Read the full bull and bear case on INCY, including what would have to change to break either one. Walnut is not an investment adviser.

Has Incyte Corporation (INCY) split its stock?

No. Incyte Corporation (INCY) has not split its stock in the last 10 years. The statement covers only the window we check, so an older split in the company’s history is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.

How is Incyte Corporation (INCY) valued?

Market cap, P/E and dividend yield at today's price are in the INCY key stats above. The business figures below come from Incyte Corporation's reported results as of October 2026 and change when it next reports.

  • Revenue (TTM): ~$5.8B
  • Q2 2026 revenue: ~$1.67B (up ~38% YoY)
  • Margins (operating / net): ~42% / ~28%
  • Net income (TTM): ~$1.6B (EPS ~$7.85)
  • Cash / debt: ~$4.5B / ~$38M
  • Dividend: None

As of October 2026: Incyte trades at about 14.5x trailing and 13x forward earnings, a modest multiple for a profitable biopharma growing revenue near 38% in its latest quarter, which reflects investor caution about the 2028 Jakafi cliff. Near-term reported earnings will be noisy, with consensus calling for a Q3 2026 loss and full-year 2026 EPS of about $3.12 before a rebound toward $8.68 in 2027. The 24 covering analysts lean buy, with a mean target near $130 against a close of about $114 on October 16, 2026.

Which ETFs hold Incyte Corporation (INCY)?

If you want INCY exposure as part of a larger bundle, these ETFs hold it meaningfully. Weights are approximate and refresh quarterly.

ETFName% in INCYExpense ratio
SCHMSchwab U.S. Mid-Cap ETF0.44%0.03%

What themes does Incyte Corporation (INCY) fit?

These are the investment theses INCY naturally fits into. Each links to a full theme guide listing every other stock that belongs and the ETFs commonly used as a passive proxy.

Who competes with Incyte Corporation (INCY)?

Large-cap oncology and hematology peers

Bristol Myers Squibb, Novartis, and AbbVie compete in blood cancers and solid tumors with far larger budgets and are increasingly aggressive in combination therapies, the same area Incyte is pursuing to extend the Jakafi platform.

Dermatology and inflammation / JAK rivals

In skin and immune-mediated disease, Opzelura competes for share against systemic JAK inhibitors like AbbVie's Rinvoq and Eli Lilly's Olumiant, plus Pfizer and Regeneron. Incyte no longer holds a JAK-inhibitor monopoly.

Mid-cap biotech and future generics

Incyte sits alongside other mid-cap biotechs racing to diversify pipelines, and after December 2028 it faces generic ruxolitinib makers who can undercut Jakafi once US exclusivity lapses.

What stocks are similar to Incyte Corporation (INCY)?

Other names that sit close to INCY: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. They are useful if you want to spread one thesis across several tickers.

How to invest in Incyte Corporation (INCY)

There are three common ways to get INCY exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it (SCHM), which spreads the position across many companies. Or build it into a focused thematic portfolio, so INCY sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where INCY fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

The bottom line on Incyte Corporation (INCY)

INCY pairs a highly profitable but concentrated Jakafi franchise with a real 2028 patent cliff. A record Q2 2026 (revenue ~$1.67 billion, up ~38%) and a stock up ~12% YTD show the diversification is gaining ground, but the story is still pipeline and new launches racing the clock.

More on Incyte Corporation (INCY)

Whether INCY is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is INCY a buy or a sell?, and where the stock could go from here in the INCY stock forecast.

For income investors, whether INCY pays a dividend and how the payout looks is covered in does INCY pay a dividend? And to weigh INCY against a peer, read the full side-by-side comparisons: INCY vs VRTX and INCY vs REGN.

Wondering how INCY fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about Incyte Corporation

Ask Walnut's AI anything about INCY and see how it fits what you own.

FAQ

What does Incyte do?

+

Incyte is a biopharmaceutical company focused on oncology, hematology, and dermatology. Its lead drug is Jakafi (ruxolitinib), a JAK inhibitor for myelofibrosis, polycythemia vera, and graft-versus-host disease, and it also sells the Opzelura skin cream and a growing portfolio of hematology and oncology medicines.

Why does Jakafi's 2028 patent matter so much?

+

Jakafi generates the largest share of Incyte's revenue, so its US loss of exclusivity in December 2028 is the single biggest overhang on the stock. Once generic ruxolitinib can enter, Jakafi sales are expected to decline, which is why Incyte is racing to build non-Jakafi revenue before then.

How fast is Incyte growing?

+

Quickly. Revenue over the last twelve months was about $5.8 billion, up from $5.14 billion in full-year 2025, and Q2 2026 revenue of about $1.67 billion rose roughly 38% year over year. Non-Jakafi products like Opzelura and the newer hematology/oncology drugs have been growing especially fast. Analysts expect about $5.94 billion of revenue for 2026 and about $6.25 billion for 2027.

Is Incyte profitable?

+

Yes. Incyte earned about $1.6 billion over the last twelve months (trailing EPS of about $7.85) with an operating margin near 42%, and it held about $4.5 billion in cash against roughly $38 million of debt at mid-2026. Analysts do expect a reported loss in Q3 2026, so quarterly profits may dip before recovering. The balance sheet gives it capacity to fund R&D and potential business development to offset the Jakafi cliff.

Who are Incyte's main competitors?

+

In oncology and hematology, Incyte competes with larger companies like Bristol Myers Squibb, Novartis, and AbbVie. In dermatology and inflammation, Opzelura competes against systemic JAK inhibitors such as AbbVie's Rinvoq and Eli Lilly's Olumiant, plus Pfizer and Regeneron.

What is Incyte's valuation like?

+

As of October 16, 2026, Incyte carries a market cap around $23 billion, a trailing P/E near 14.5x, a forward P/E near 13x, and a price-to-sales ratio near 4x. It pays no dividend. The relatively modest multiple reflects strong recent earnings alongside investor caution about the 2028 patent cliff.

How did Incyte do in its latest quarter?

+

In Q2 2026 (reported in the summer), Incyte posted revenue of about $1.67 billion, up roughly 38% year over year and about 11% above analyst estimates, and EPS of $3.09 against a $2.15 consensus. Net income was about $586 million. Full-year revenue guidance issued with the quarter came in below what analysts had expected. Q3 2026 results are scheduled for October 29, 2026, with consensus at about $1.48 billion of revenue and a loss of about $3.84 per share.

How has INCY stock performed in 2026?

+

INCY closed at about $113.75 on October 16, 2026, up about 12% year to date and about 30% over the past year. The shares pulled back about 9% over the past month and sit below their 52-week high of about $132.60 (the low was about $84). Analysts' mean price target is about $129.50.

What are the biggest risks with INCY?

+

The main risks are heavy revenue concentration in Jakafi and its 2028 loss of exclusivity, clinical trial and regulatory setbacks (such as the FDA rejection of an extended-release Jakafi), volatile reported earnings around one-time charges, and intensifying competition from larger biopharma peers. If pipeline and newer products do not scale in time, a revenue gap could emerge late this decade.

Is INCY a good investment?

+

Walnut is not an investment adviser and does not make buy or sell recommendations. Whether INCY fits a portfolio depends on your own goals, risk tolerance, and time horizon, and on how you weigh its strong current cash flow against the 2028 Jakafi patent cliff and pipeline execution risk. Consider researching the fundamentals and consulting a licensed professional.

Guides that feature INCY

INCY is one of the names covered in these guides. Each one puts the stock next to its peers so you can see where it fits rather than judging it alone.

Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Incyte Corporation's investor relations page or your broker before making investment decisions.